Braxia CEO Dr. Roger McIntyre said, “Today’s announcement is the first of what we intend to be a series of growth developments and acquisitions to our clinical network.” Braxia Scientific Corp. is a medical research ... [Read]
Dimerix (ASX:DXB), a diabetes-focused biotech company, has signed a clinical trial agreement with the Australian Centre for Accelerating Diabetes Innovations (ACADI) to test its oral medicinal product DMX-200 in diabetic kidney disease patients. In addition ... [Read]
Two things are happening right now that investors should have on their radars. The first is that some microcap stocks are doing very well. This is evidenced in part by the iShares Microcap ETF (IWC) ... [Read]
PR Newswire MONMOUTH JUNCTION, N.J. , May 19, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces ... [Read]
– Nonclinical data demonstrate that a single intracochlear administration of an AAVAnc80 vector led to durable restoration of auditory function and was well tolerated, supporting planned clinical development of AK-OTOF for the treatment of OTOF ... [Read]
PR Newswire SAN DIEGO and SHANGHAI , May 15, 2022 /PRNewswire/ — Inmagene Biopharmaceuticals (“Inmagene”) announces that today the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for the drug ... [Read]
This launch coincides with the inaugural IgAN Awareness Day STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) — Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the launch of IgAN Connect, a new ... [Read]
Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia) New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicles ... [Read]
Silk Road Medical (SILK) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.31 per share a year ago. ... [Read]
REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster presentations highlighting three of the Company’s gene ... [Read]